Compare Ginkgo Bioworks Holdings Inc (DNA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Procter & Gamble Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while Procter & Gamble Co trades at $146.24 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 576× Ginkgo Bioworks Holdings Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | PG | |
|---|---|---|
Market Cap | $590.53M | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $167.18 |
52-Week Low | $5.48 | $138.10 |
Enterprise Value | $627.78M | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Procter & Gamble (PG) trades at $145.81, down 1.73% on the day, with a neutral technical signal and mixed moving averages. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.42. Strong fundamentals include a 19.16% net income margin and $17.82B operating cash flow for 2025, though valuation ratios like P/E of 21.36 and P/S of 4.09 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.
PG offers stability with a 69-year dividend growth streak and analyst consensus price target of $161.71, implying 11% upside. Risks include premium valuation pressures and soft demand concerns. The stock remains a defensive play amid market volatility, supported by institutional bullishness but tempered by modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
